苏氨酸乙酯盐酸盐(1:1) | 28528-83-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 苏氨酸乙酯盐酸盐(1:1)
• 英文名称: hydrochloride of the ethyl ester of threonine
• 英文别名: L-glutamic acid ethyl ester hydrochloride；Ethyl DL-threoninate hydrochloride；ethyl (2S)-2-amino-3-hydroxybutanoate;hydrochloride
• CAS: 28528-83-8；33368-36-4；39994-70-2；62365-20-2
• 化学式: C₆H₁₄NO₃*Cl
• 分子量: 183.635
• InChiKey: WHKKNTASOQMDMH-YKXIHYLHSA-N

物化性质

• 熔点：
  117-118 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.32
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  72.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苏氨酸乙酯盐酸盐(1:1) 在 钯 氢气 、 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 、 三乙胺 作用下， 反应 76.33h， 生成 ethyl ester of N-benzyloxycarbonylthreonyltyrosylthreonine
  参考文献：
  名称：

  Synthesis of the hexapeptide 11–16 of the natural sequence of human calcitonin

  摘要：

  DOI：

  10.1007/bf00579150

文献信息

• [EN] PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLOPYRIMIDINES ET LEUR UTILISATION COMME INHIBITEUR DE LA PDE10
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2011105628A1

  公开（公告）日：2011-09-01

  The present invention relates to a compound represented by formula [I]: wherein: R1 is hydrogen, halogen, lower alkyl or cyano; Ring A is an optionally substituted heterocyclic group; Ring B is an optionally substituted 3 to 6-membered monocyclic group; and Y is optionally substituted amino, optionally substituted cyclic amino, optionally substituted aliphatic 3 to 6-membered monocyclyloxy, optionally substituted lower alkyl or optionally substituted lower alkyl-O-, or a pharmaceutically acceptable salt thereof, and to their use as PDE10 inhibitor.

  本发明涉及一种由式[I]表示的化合物，其中：R1是氢、卤素、较低的烷基或氰基；环A是可选择取代的杂环基团；环B是可选择取代的3至6元杂环基团；Y是可选择取代的氨基、可选择取代的环氨基、可选择取代的脂肪族3至6元单环氧基、可选择取代的较低的烷基或可选择取代的较低的烷基-O-，或其药学上可接受的盐，以及它们作为PDE10抑制剂的用途。
• PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS
  申请人：Kawanishi Eiji

  公开号：US20120309754A1

  公开（公告）日：2012-12-06

  The present invention relates to a compound represented by formula [I]: wherein: R 1 is hydrogen, halogen, lower alkyl or cyano; Ring A is an optionally substituted heterocyclic group; Ring B is an optionally substituted 3 to 6-membered monocyclic group; and Y is optionally substituted amino, optionally substituted cyclic amino, optionally substituted aliphatic 3 to 6-membered monocyclyloxy, optionally substituted lower alkyl or optionally substituted lower alkyl-O—, or a pharmaceutically acceptable salt thereof, and to their use as PDE10 inhibitor.

  本发明涉及一种由式[I]表示的化合物： 其中：R1是氢、卤素、较低的烷基或氰基；环A是可选取代的杂环基团；环B是可选取代的3至6成员的单环基团；以及Y是可选取代的氨基、可选取代的环状氨基、可选取代的脂肪族3至6成员的单环氧基、可选取代的较低烷基或可选取代的较低烷基-O-，或其药学上可接受的盐，并且作为PDE10抑制剂使用。
• Synthesis, stereochemistry and decomplexation of (η-arene)(η-cyclopentadienyl) iron(II) hexafluorophosphate complexes containing amino acid side chains. A route to N-arylamino acids
  作者：Roger M.G. Roberts、Emma Johnsen

  DOI：10.1016/s0022-328x(97)00292-1

  日期：1997.10

  [(eta-Substituted arene)(eta-cyclopentadienyl)Fe][PF6] complexes with amino acid side chains on the arene ring have been prepared by reaction of [(eta-haloarene)(eta-cyclopentadienyl)Fe][PF6] complexes with amino acids and amino acid eaters under various conditions. Evidence is presented from H-1-and C-13-NMR spectroscopy for the existence of conformational isomers resulting from restricted rotation about the arene-nitrogen bond. Where a chlorine substituent is also present in the complexed arene, diastereoisomers can be separated by column chromatography. Decomplexation of the complexes is reported in strongly basic media or using 1,8-phenanthroline in light-catalysed reactions offering a new route to N-arylamino acids. (C) 1997 Elsevier Science S.A.
• US5210290A
  申请人：——

  公开号：US5210290A

  公开（公告）日：1993-05-11
• US8969376B2
  申请人：——

  公开号：US8969376B2

  公开（公告）日：2015-03-03